Explore

Trendline Trendline
Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study

Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study

Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study
Trendline Trendline
Otsuka's VOYXACT Shows Promising Results in Preserving Kidney Function in IgA Nephropathy Patients

Otsuka's VOYXACT Shows Promising Results in Preserving Kidney Function in IgA Nephropathy Patients

Otsuka's VOYXACT Shows Promising Results in Preserving Kidney Function in IgA Nephropathy Patients
Rapid Read Rapid Read
Clinical Trials Face Major Recruitment Challenges, Impacting Drug Development

Clinical Trials Face Major Recruitment Challenges, Impacting Drug Development

Clinical trials are experiencing significant recruitment challenges, with approximately 80% failing to meet their enrolment timelines. This issue is largely due to a lack of engagement and education among potential participants, particularly in marginalized communities. The delay in recruitment not only postpones the availability of new treatments but also incurs substantial financial losses for sponsors. The industry has made strides in improving trial processes, such as protocol design and decentralized monitoring, but recruitment remains a bottleneck. The integration of AI is seen as a potential solution to streamline recruitment by identifying and engaging eligible patients more effectively.
Trendline Trendline
Lundbeck Presents New Migraine Treatment Data at American Headache Society Meeting

Lundbeck Presents New Migraine Treatment Data at American Headache Society Meeting

Lundbeck Presents New Migraine Treatment Data at American Headache Society Meeting
Trendline Trendline
Satsuma Pharmaceuticals to Present Migraine Treatment Findings at AHS Meeting

Satsuma Pharmaceuticals to Present Migraine Treatment Findings at AHS Meeting

Satsuma Pharmaceuticals to Present Migraine Treatment Findings at AHS Meeting
Rapid Read Rapid Read
Lundbeck Unveils New Migraine Data at American Headache Society Meeting

Lundbeck Unveils New Migraine Data at American Headache Society Meeting

Lundbeck US has presented new data on its migraine treatment VYEPTI (eptinezumab-jjmr) at the American Headache Society's 68th Annual Scientific Meeting. The data includes findings from several trials, such as the INFUSE, DELIVER, SUNSET, and RESOLUTION trials, which focus on the effectiveness of VYEPTI in reducing migraine symptoms and improving patient-reported outcomes. The presentations highlighted the drug's impact on cognitive symptoms and headache hours, as well as its consistent efficacy across different countries. Additionally, new data on bocunebart, an investigational drug targeting PACAP for migraine prevention, was also shared.
Rapid Read Rapid Read
Toregem Biopharma Accelerates Human Trials for Tooth Regeneration

Toregem Biopharma Accelerates Human Trials for Tooth Regeneration

Toregem Biopharma, a Japanese pharmaceutical company, is accelerating its plans for human trials of a tooth regeneration treatment. The company has developed a method to inhibit a gene that suppresses tooth growth, potentially allowing for the regeneration of new teeth. This approach has shown promise in preclinical studies, where it successfully restored teeth in mice. Toregem has raised $5.3 million to support the development of this treatment, with plans to conduct a Phase 2 clinical trial in Japan. The treatment aims to offer a new solution for dental patients, moving beyond traditional options like dentures and implants.
Trendline Trendline
Structure Therapeutics' Obesity Drug Aleniglipron Shows Promising Weight Loss Results in Phase 2b Trial

Structure Therapeutics' Obesity Drug Aleniglipron Shows Promising Weight Loss Results in Phase 2b Trial

Structure Therapeutics' Obesity Drug Aleniglipron Shows Promising Weight Loss Results in Phase 2b Trial
Trendline Trendline
Otsuka's VOYXACT Shows Promise in Preserving Kidney Function in IgA Nephropathy

Otsuka's VOYXACT Shows Promise in Preserving Kidney Function in IgA Nephropathy

Otsuka's VOYXACT Shows Promise in Preserving Kidney Function in IgA Nephropathy
Trendline Trendline
Otsuka Pharmaceuticals' Voyxact Shows Promise in IgA Nephropathy Phase 3 Trial

Otsuka Pharmaceuticals' Voyxact Shows Promise in IgA Nephropathy Phase 3 Trial

Otsuka Pharmaceuticals' Voyxact Shows Promise in IgA Nephropathy Phase 3 Trial
Rapid Read Rapid Read
Genetic Variants May Limit Effectiveness of Diabetes Drug Ozempic

Genetic Variants May Limit Effectiveness of Diabetes Drug Ozempic

A study by Stanford Medicine and international collaborators has found that genetic variants may cause resistance to GLP-1 receptor agonists, a class of diabetes medications that includes Ozempic. About 10% of people carry these variants, which result in higher levels of the hormone GLP-1 but reduced effectiveness in blood sugar regulation. The research, published in Genome Medicine, involved experiments in humans and mice, and analyzed clinical trial data. The findings suggest that genetic makeup could influence the effectiveness of these drugs, potentially leading to more personalized diabetes treatment strategies.
Rapid Read Rapid Read
Structure Therapeutics Publishes Phase 2b Study Results for Obesity Treatment

Structure Therapeutics Publishes Phase 2b Study Results for Obesity Treatment

Structure Therapeutics has published results from its Phase 2b ACCESS clinical trial of aleniglipron, an oral small molecule GLP-1 receptor agonist for obesity, in Nature Medicine. The study demonstrated significant weight loss in participants, with continued weight reduction observed in an open-label extension phase. The trial also showed improvements in cardiovascular risk factors. These findings support the design of an upcoming Phase 3 program, set to begin in the third quarter of 2026. Aleniglipron's potential as a once-daily oral treatment could offer a new option for obesity management.